PROM1 and neoplasm: A strong negative correlation of CD133 levels with clinical stage of TNBC tumors was firstly observed by Zhao et al. [28], and the use of CD133 to detect circulating tumor cells in TNBC patients ratified its role in prognosis of this breast cancer subtype [29].